Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026

RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that new long-term efficacy and safety data from the Company’s ongoing Transform-HTN open-label extension trial of the aldosterone synthase inhibitor lorundrostat will be featured in a late-breaking science presentation at the American Heart Association Scientific Sessions 2026, taking place November 6-9 in Chicago, IL.

Title: Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat, a Novel Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension